PCR Journal Club

This study demonstrated, for the first time, that PPG - an index to characterize focal vs. diffuse disease - can predict optimal functional revascularization outcomes (post-PCI FFR ≥ 0.88) more accurately than FFR alone.

This analysis shows that diabetic patients undergoing revascularization face substantially higher 5-year rates of all-cause mortality, myocardial infarction, repeat revascularizations, and stroke compared to non-diabetic patients.

This study highlights the TRISCORE's role in assessing risk for patients undergoing TTVI. Despite limitations, TRISCORE effectively identifies high-risk patients, aiding decision-making in a complex landscape of valvular heart disease management.

This trial sought to compare the procedural and clinical outcomes of ACURATE neo/neo2 and EVOLUT R/PRO/Pro+ valves for ViV procedures.

In this large single centre registry investigators demonstrated that with the exception of endothelium independent epicardial coronary artery dysfunction, CVDys diagnosed by interventional functional assessment is correlated with adverse cardiac and cerebrovascular events.

The trial aimed to establish the non-inferiority of QCA-guided PCI compared to IVUS-guided PCI with respect to the primary endpoint of TLF at 12 months, defined as a composite of cardiac death, target vessel MI, or ischemia-driven target lesion revascularization.

This study demonstrates that, at 5 years post TAVI in patients with an indication for OAC, the net clinical benefit did not differ between the VKA and DOAC groups.

This study, based on the trial inclusion and exclusion criteria, aimed to compare outcomes in a contemporary “real-world” T-TEER cohort stratified by TRILUMINATE eligibility or ineligibility.

The results of this sub-analysis of the ALPHEUS trial show that complex PCI criteria are present in a large percentage of patients with chronic coronary syndrome and are associated with higher rates of both periprocedural events and MACE than non-complex PCI.

The NOTION trial provides the first ten-year data comparing clinical outcomes and valve durability between TAVI and SAVR in the lower risk population.